Durvalumab and tremelimumab before surgery for mesothelioma
Part of Cancer clinical trials.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have mesothelioma that doctors think might be fully removed with surgery, based on CT/PET scans and a surgeon’s assessment
- Be able to have planned surgery after starting the study (either pleurectomy/decortication or extrapleural pneumonectomy)
- Be 18 or older, and well enough to participate (ECOG performance status 0–1)
- Have adequate blood counts and organ function (including kidney function and liver enzyme levels within limits)
- Have no prior treatment with PD-1 or PD-L1 medicines (including durvalumab) before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy for people with malignant mesothelioma that cannot be treated with surgery or radiation. It may be an option whether you are starting treatment for the first time or have had up to three prior treatments.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.